Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 99Myelodysplastic Syndromes 56Leukemia, Myelomonocytic, Chronic 23Leukemia 17Recurrence 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Non-Hodgkin 10Hematologic Neoplasms 9Multiple Myeloma 8Hodgkin Disease 8Neoplasms 6Myeloproliferative Disorders 6Leukemia, Myeloid 6Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Non-Small-Cell Lung 6Myelodysplastic-Myeloproliferative Diseases 5Lymphoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Sarcoma 4Primary Myelofibrosis 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Leukemia, Biphenotypic, Acute 4Head and Neck Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Melanoma 3Lymphoma, T-Cell, Peripheral 3

Interventions

Cytarabine 30fludarabine phosphate 13Etoposide 12Cyclophosphamide 11Mitoxantrone 10Peripheral Blood Stem Cell Transplantation 9Decitabine 9Tacrolimus 7Filgrastim 7Mycophenolic Acid 6Bortezomib 6Idarubicin 5Flow Cytometry 5Daunorubicin 5Antilymphocyte Serum 5tipifarnib 4sargramostim 4Whole-Body Irradiation 4Vorinostat 4Radiotherapy 4Cyclosporine 4Cord Blood Stem Cell Transplantation 4Clofarabine 4Busulfan 4alvocidib 3Polymerase Chain Reaction 3Melphalan 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3tanespimycin 2selinexor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Congenital Abnormalities × Azacitidine × Clear all
NCT01839240 2020-05-15

Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia

University of Chicago

Phase 1 Completed
50 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00624936 2017-08-22

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
MyeloidOther hematologic neoplasm

Congenital Abnormalities, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡